

MINIREVIEW

Superoxide Dismutase and Pulmonary Oxygen Toxicity (43600A)



MIN-FU TSAN¹

Research Service, Samuel S. Stratton Department of Veterans Affairs Medical Center, and Departments of Physiology and Cell Biology, and Medicine, Albany Medical College, Albany, New York 12208

Abstract. Three forms of superoxide dismutase (SOD) exist in the lung: CuZnSOD, MnSOD and extracellular SOD. Evidence suggests that both CuZnSOD and MnSOD are important in pulmonary defense against oxygen toxicity. Enhancement of pulmonary levels of CuZnSOD by transgenic overexpression of CuZnSOD, or tracheal insufflation of liposome-encapsulated or polyethylene glycol-conjugated CuZnSOD, protects animals against oxygen toxicity. Likewise, transgenic overexpression of MnSOD, or induction of endogenous MnSOD by endotoxin, tumor necrosis factor, or interleukin 1, also protects animals against oxygen toxicity. The role of extracellular SOD in the pulmonary defense against oxygen toxicity is not clear.

[P.S.E.B.M. 1993, Vol 203]

A significant fraction of biologic oxygen reduction, enzymatic or nonenzymatic, occurs via the pathway of univalent reduction resulting in the generation of superoxide anion (O_2^-). Superoxide anion is a reactive oxygen free radical. It is also capable of producing potent oxidants, e.g., hydrogen peroxide (H_2O_2) (via enzymatic or spontaneous dismutation [Reaction 1]), or hydroxyl radical (OH^\bullet) (via Haber-Weiss reaction [Reaction 2]) (1):



The production of these reactive oxygen species (O_2^- , H_2O_2 , and OH^\bullet) is markedly accentuated under hyperoxic conditions leading to tissue (especially pulmonary) injury (2). Considerable evidence suggests

that during the hyperoxic exposure, reactive oxygen species are produced both intracellularly by lung parenchymal cells and extracellularly by infiltrating neutrophils (3–5).

Superoxide dismutase (SOD) is a family of enzymes that catalyze the dismutation of O_2^- to H_2O_2 and O_2 (Reaction 1). By rapidly eliminating O_2^- , SOD reduces the tissue concentrations of O_2^- and OH^\bullet (Reaction 2). Thus, if lung tissue contains sufficient quantities of catalase and glutathione (GSH) peroxidase to dispose H_2O_2 , augmentation of pulmonary SOD has the potential to protect animals against pulmonary oxygen toxicity. This minireview summarizes our current understanding of the role of SOD in the protection against pulmonary oxygen toxicity.

Superoxide Dismutase

Three forms of SOD, with distinct distribution and characterized by their metal components, exist in eukaryotes: CuZnSOD, MnSOD, and extracellular SOD which also contains Cu and Zn (1, 6). Intracellular CuZnSOD constitutes approximately 85%–90% of the total cellular SOD activity. Although it is usually regarded as a cytosolic enzyme, recent evidence suggests that the majority of this enzyme may actually be located in peroxisomes (7). MnSOD, which constitutes approx-

¹ To whom requests for reprints should be addressed at Research Service, Stratton VA Medical Center, Albany, NY 12208.

imately 10%–15% of the total cellular SOD activity, is located in mitochondria. It is an inducible enzyme; induction of MnSOD in eukaryotes has been demonstrated following exposure to irradiation (8), or hyperoxia (9), or following treatment with paraquat (10), tumor necrosis factor (TNF) (11–13), interleukin 1 (IL-1) (12, 14), or endotoxin (12, 15). Extracellular SOD is a Cu,Zn-containing enzyme distinct from intracellular CuZnSOD. It is the dominant SOD isoenzyme in the plasma; however, its tissue content is much lower than that of CuZnSOD or MnSOD (6). Little is known about the biologic function of extracellular SOD, including its role in the defense against oxygen toxicity.

CuZnSOD and Oxygen Toxicity

Considerable evidence supports the importance of cytosolic or peroxisomal CuZnSOD in the pulmonary defense against oxygen toxicity. A boy with partial monosomy 21 and diminished CuZnSOD activity (in humans, the gene encoding for CuZnSOD is located on chromosome 21) was found to have a markedly increased sensitivity to pulmonary oxygen toxicity, which suggests that normal levels of CuZnSOD are essential for the pulmonary defense against oxygen toxicity (16). Survival advantage was noted in young (2.5 months old) but not old (5 months old), female but not male, mice with transgenic overexpression of pulmonary CuZnSOD, exposed to 100% O₂ at a reduced atmospheric pressure (630 torr), but not at the sea level atmospheric pressure (760 torr) (17). It is not clear why the protective effect of increased pulmonary CuZnSOD was noted only in a subgroup of young, female, transgenic mice under reduced atmospheric pressure.

Exposure of rats to a sublethal dose of normobaric O₂ (85% or 90%) for 7 days results in a significant increase in pulmonary levels of CuZnSOD, MnSOD, catalase, and GSH peroxidase (18, 19). These antioxidant enzyme-augmented animals become tolerant to a lethal dose (>95%) of O₂. Likewise, rats pre-exposed to hypoxia (10% O₂) for 3 days also become tolerant to lethal hyperoxia (20). This hypoxia-induced oxygen tolerance is associated with increased pulmonary levels of total SOD, catalase, and GSH peroxidase. Neonatal rats, mice, and rabbits are more resistant to lethal doses of O₂ than their adult counterparts (21–23). This is due in part to these neonatal animals' ability to increase pulmonary levels of total SOD, catalase, and GSH peroxidase within 24 hr of O₂ exposure. Since antioxidant enzymes other than pulmonary CuZnSOD are also increased under the above conditions, increased level of pulmonary CuZnSOD may not be solely responsible for the increased tolerance to pulmonary oxygen toxicity.

Considerable effort has been made in recent years to enhance oxygen tolerance by increasing pulmonary SOD activity. Because of the extremely short plasma

half-life (a few minutes) and poor cellular uptake of CuZnSOD, administration of CuZnSOD by intravenous injection or aerosol inhalation does not protect animals against oxygen toxicity (24, 25). Liposome encapsulation or polyethylene glycol (PEG) conjugation of CuZnSOD has been used successfully to prolong its plasma half-life and increase cellular uptake of the enzyme (25–27). Tracheal insufflation of liposome-encapsulated CuZnSOD (28) or PEG-CuZnSOD (29) protects rats against oxygen toxicity. However, intravenous or intraperitoneal administration of liposome-encapsulated CuZnSOD or PEG-CuZnSOD does not protect animals against oxygen toxicity, unless they are co-administered with liposome-encapsulated catalase or PEG-catalase, respectively (27, 30). This may be due in part to the fact that at a similar dosage, tracheal insufflation of PEG-CuZnSOD increases pulmonary SOD activity to a much greater extent than intravenous injection (29).

Intraperitoneal administration of a sublethal dose of endotoxin (500 µg/kg) to rats exposed to hyperoxia also results in increased lung total SOD activity, decreased O₂-induced lung damage, and an improved survival rate (31). The endotoxin- and hyperoxia-induced increase in pulmonary SOD activity was thought to be due to an increase in CuZnSOD, since the increased pulmonary SOD activity could be abolished by pretreatment with diethyldithiocarbamate, a Cu-chelating agent and an inhibitor of CuZnSOD (32). Furthermore, levels of pulmonary CuZnSOD mRNA and specific protein were also found to be slightly increased in endotoxin-treated and hyperoxia-exposed rats, suggesting the possible role of CuZnSOD in the protection against oxygen toxicity (33, 34). However, levels of pulmonary MnSOD mRNA, specific (immunoreactive) protein, or enzyme activity were not measured in the above studies. In addition, diethyldithiocarbamate is a nonspecific inhibitor and may have effects other than inhibition of CuZnSOD to account for the observed response. A recent abstract from the same group of investigators (35) reported that endotoxin-induced oxygen tolerance was not associated with an increase in CuZnSOD. Instead, it was associated with a marked increase in levels of pulmonary MnSOD mRNA and enzyme activity.

MnSOD and Oxygen Toxicity

Despite its strategic location in mitochondria, a major site of O₂⁻ production under hyperoxic conditions (3), the potential role of MnSOD in the pulmonary defense against oxygen toxicity has not attracted much attention. This is in part due to the fact that MnSOD constitutes a minor fraction of the total pulmonary SOD activity and its activity is difficult to measure. Most previous studies have only measured total pulmonary SOD activity, which may overlook a

significant alteration of MnSOD activity. The above-mentioned increase in pulmonary SOD activity within 24 hr of O₂ exposure in neonatal rats is accounted for solely by an increase in MnSOD activity (23). The recent demonstration that endotoxin, TNF, or IL-1 selectively induces MnSOD mRNA, leading to increased MnSOD specific protein and enzyme activity, without affecting the levels of other antioxidant enzymes, including CuZnSOD, catalase, and GSH peroxidase (11–15), has called attention to the potential role of pulmonary MnSOD in the protection against oxygen toxicity.

Tracheal insufflation, but not intraperitoneal injection, of a single dose (e.g., 5 µg) of TNF or IL-1 attenuates O₂-induced pulmonary injury and prolongs the survival of rats exposed to 100% O₂ (36, 37). TNF- or IL-1-insufflation-induced protection against oxygen toxicity is associated with a selective enhancement of pulmonary MnSOD mRNA, specific protein, and enzyme activity at 2.3 days (55 hr) after O₂ exposure, when control rats start to die of oxygen toxicity (36–39). Exposure of control rats to 100% O₂ also results in a marked enhancement of pulmonary MnSOD mRNA. However, this is not associated with an increase in pulmonary MnSOD specific protein or enzyme activity. Instead, at 2.3 days after O₂ exposure, the levels of pulmonary MnSOD specific protein and enzyme activity are reduced by approximately 30% (36–39). TNF and IL-1 act synergistically in protecting rats against oxygen toxicity and in enhancing endothelial cell MnSOD, but not CuZnSOD, mRNA levels. Interleukin 6, which provides no protective effect in rats against oxygen toxicity and has no apparent effect on endothelial cell MnSOD mRNA levels, markedly enhances TNF- and IL-1-induced increases in endothelial cell MnSOD mRNA levels and in oxygen tolerance in rats (40). Similarly, D factor (differentiation-inducing factor) and growth hormone enhance the TNF-induced increase in pulmonary MnSOD mRNA, they also enhance TNF- induced oxygen tolerance (41).

These results support an important role of MnSOD in the pulmonary defense against oxygen toxicity. For example, failure of hyperoxia-exposed rats to increase pulmonary MnSOD protein and enzyme activity in the presence of an elevated level of MnSOD mRNA may contribute to the pathogenesis of pulmonary oxygen toxicity, and enhancement of pulmonary MnSOD plays an important role in the cytokine-induced protection against oxygen toxicity. In a recent abstract, Massaro *et al.* (35) also reported that exposure of rats to >95% O₂ resulted in a markedly elevated level of pulmonary MnSOD mRNA, while the activity of pulmonary MnSOD was reduced by approximately 50%. Furthermore, endotoxin treatment resulted in a selective enhancement of pulmonary MnSOD mRNA and enzyme activity in O₂-exposed rats, which suggests that en-

hanced pulmonary MnSOD, but not other antioxidant enzymes including CuZnSOD, plays an important role in the endotoxin-induced oxygen tolerance (35). Protection of mice against oxygen toxicity by TNF is also associated with an induction of pulmonary MnSOD mRNA (42). Further support of the importance of MnSOD in the host defense against oxygen toxicity comes from a recent study of transgenic mice in which expression of human MnSOD mRNA in Type II alveolar and non-ciliated bronchiolar epithelial cells confers protection against pulmonary oxygen toxicity (43).

The mechanism by which endotoxin, cytokines, or hyperoxia enhances MnSOD mRNA has been studied in cultured cells and lung tissues. Visner *et al.* (12, 44) reported that endotoxin-induced enhancement of MnSOD mRNA levels in rat pulmonary epithelial cells or in porcine pulmonary artery endothelial cells was completely inhibited by the RNA synthesis inhibitor, actinomycin D, which suggests that induction of MnSOD mRNA by endotoxin was regulated at least in part at the transcriptional level. Likewise, induction of MnSOD mRNA by TNF or IL-1 in a number of cell types is dependent upon *de novo* transcription requiring no *de novo* protein synthesis (45, 46). Massaro *et al.* (35) reported that the O₂-induced increase in pulmonary MnSOD mRNA was due to an increase in MnSOD mRNA stability. Furthermore, in endotoxin-treated rats exposed to normoxia, the increased pulmonary MnSOD mRNA level was due to an increased rate of transcription, while in endotoxin-treated rats exposed to hyperoxia, the increased level of pulmonary MnSOD mRNA was due to a combination of increased transcription and increased stability of mRNA.

A number of investigators have questioned the role of pulmonary antioxidant enzymes in endotoxin- or cytokine-induced oxygen tolerance. Hazinski *et al.* (47) reported that intravenous injection of endotoxin protected lambs against O₂-induced pulmonary injury and prolonged their survival. This endotoxin-induced protection against oxygen toxicity was not associated with any increase in pulmonary antioxidant enzymes when control animals were suffering from severe oxygen toxicity. Similar observations were made by White *et al.* (48, 49), who gave a combination of IL-1 and TNF to rats in split doses by intraperitoneal and intravenous injections, and by Berg *et al.* (50), who gave sera containing high levels of TNF and IL-1 from rats pretreated with endotoxin to rats by intravenous injection. All these investigators have concluded that an increase of pulmonary antioxidant enzymes is not necessary for the protection against oxygen toxicity. However, none of these studies has measured pulmonary MnSOD activity; instead, only total lung SOD activities were measured. Because MnSOD constitutes a minor fraction of the total cellular SOD, it is possible that an enhance-

ment of lung MnSOD activity may have been overlooked if one determined only total SOD activity.

Conclusion and Directions for Future Studies

Oxygen is an important therapeutic modality for patients with severe hypoxemia. However, prolonged exposure to a high partial pressure of O₂ causes tissue injury which may exacerbate the existing lung pathology (51). At present there is no practical means of preventing oxygen toxicity. The above Minireview clearly indicates that both CuZnSOD and MnSOD are essential in the pulmonary defense against oxygen toxicity, and that enhancement of pulmonary levels of CuZnSOD or MnSOD, e.g., by administration of exogenous CuZnSOD (liposome encapsulated or PEG conjugated) or induction of endogenous MnSOD, can protect animals against oxygen toxicity. This review also raises some important questions for future investigation. (i) Why do animals respond to O₂ exposure by raising pulmonary MnSOD mRNA, but fail to increase pulmonary MnSOD protein or enzyme activity, and succumb to oxygen toxicity? (ii) What is the cellular distribution of, or cell type(s) responsible for, the increased level of pulmonary MnSOD in cytokine- or endotoxin-treated animals? (iii) What is the mechanism for the preferential protective effect of cytokines, liposome-encapsulated CuZnSOD, or PEG-CuZnSOD when given by tracheal route as compared with intravenous or intraperitoneal injection? What is the role of alveolar macrophages in this regard? There is good reason to believe that continued investigation will eventually lead to the development of practical means of preventing oxygen toxicity.

This work was supported by the Department of Veterans Affairs Medical Research Service. The author thanks Rhoda Drumm for secretarial assistance.

1. Fridovich I. Oxygen radicals, hydrogen peroxide and oxygen toxicity. In: Pryor WA, Ed. *Free Radicals in Biology*. New York: Academic Press, Vol 1: pp239-277, 1976.
2. Frank L, Massaro D. Oxygen toxicity. *Am J Med* **69**:117-126, 1980.
3. Freeman BA, Crapo JD. Hyperoxia increases oxygen radical production in rat lungs and lung mitochondria. *J Biol Chem* **256**:10986-10992, 1981.
4. Fox RB, Hoidal JR, Brown DM, Repine JE. Pulmonary inflammation due to oxygen toxicity: Involvement of chemotactic factor and polymorphonuclear leukocytes. *Am Rev Respir Dis* **123**:521-523, 1981.
5. Shasby DM, Fox RB, Harada RN, Repine JE. Reduction of the edema of acute hyperoxic injury by granulocyte depletion. *J Appl Physiol* **52**:1237-1244, 1982.
6. Marklund SL. Extracellular superoxide dismutase and other superoxide dismutase isozymes in tissues from nine mammalian species. *Biochem J* **222**:649-655, 1984.
7. Keller GA, Warner TG, Steimer KS, Hallewell RA. Cu,Zn superoxide dismutase is a peroxisomal enzyme in human fibroblasts and hepatoma cells. *Proc Natl Acad Sci USA* **88**:7381-7385, 1991.
8. Oberley LW, Kasemset St Clair D, Autor AP, Oberley TD. Increase in manganese superoxide dismutase activity in the mouse heart after X-irradiation. *Arch Biochem Biophys* **254**:69-80, 1987.
9. Housset B, Juno AF. Effects of culture conditions and hyperoxia on antioxidant enzymes in pig pulmonary artery and aortic endothelium. *Biochim Biophys Acta* **716**:283-289, 1982.
10. Krall J, Bagley AC, Mullenbach GT, Hallewell RA, Lynch RE. Superoxide mediates the toxicity of paraquat for cultured mammalian cells. *J Biol Chem* **263**:1910-1914, 1988.
11. Wong GHW, Goeddel DV. Induction of manganous superoxide dismutase by tumor necrosis factor: Possible protective mechanism. *Science* **242**:941-944, 1988.
12. Visner GA, Dougall JM, Wilson JM, Burr IA, Nick HS. Regulation of manganese superoxide dismutase by lipopolysaccharide, interleukin 1, and tumor necrosis factor. Role in the acute inflammatory response. *J Biol Chem* **265**:2856-2864, 1990.
13. Shaffer JB, Treanor CP, Del Vecchio PJ. Expression of bovine and mouse endothelial cell antioxidant enzymes following TNF- α exposure. *Free Radic Biol Med* **8**:497-502, 1990.
14. Masuda A, Longo DL, Kobayashi Y, Appella E, Oppenheim JJ, Matsushima K. Induction of mitochondria manganese superoxide dismutase by interleukin 1. *FASEB J* **2**:3087-3091, 1988.
15. Shiki Y, Meyerick BO, Brigham KL, Burr IM. Endotoxin increases superoxide dismutase in culture bovine pulmonary endothelial cells. *Am J Physiol* **252**:C436-C440, 1989.
16. Ackerman AD, Fackler JC, Tuck-Muller CM, Tarpey MM, Freeman BA, Rogers MC. Partial monosomy 21, diminished activity of superoxide dismutase, and pulmonary oxygen toxicity. *N Engl J Med* **318**:1666-1669, 1988.
17. White CW, Avraham KB, Shanley PF, Groner Y. Transgenic mice with expression of elevated levels of copper-zinc superoxide dismutase in the lungs are resistant to pulmonary oxygen toxicity. *J Clin Invest* **87**:2162-2168, 1991.
18. Crapo JD, Tierney DF. Superoxide dismutase and pulmonary oxygen toxicity. *Am J Physiol* **226**:1401-1407, 1974.
19. Kimball RE, Reddy K, Peirce TH, Schwartz LW, Mustafa MG, Cross CE. Oxygen toxicity: Augmentation of antioxidant defense mechanisms in rat lung. *Am J Physiol* **230**:1425-1431, 1976.
20. Frank L. Protection from O₂ toxicity by preexposure to hypoxia: Lung antioxidant enzyme role. *J Appl Physiol* **53**:475-482, 1982.
21. Autor AP, Frank L, Roberts RJ. Developmental characteristics of pulmonary superoxide dismutase: Relationship to idiopathic respiratory distress syndrome. *Pediatr Res* **10**:154-158, 1976.
22. Frank L, Bucher JR, Roberts RJ. Oxygen toxicity in neonatal and adult animals of various species. *J Appl Physiol* **45**:699-704, 1978.
23. Stevens JB, Autor AP. Induction of superoxide dismutase by oxygen in neonatal rat lung. *J Biol Chem* **252**:3509-3514, 1977.
24. Crapo JD, DeLong DM, Sjoström K, Hasler KR, Drew RT. The failure of aerosolized superoxide dismutase to modify pulmonary oxygen toxicity. *Am Rev Respir Dis* **115**:1027-1033, 1977.
25. Turrens JF, Crapo JD, Freeman BA. Protection against oxygen toxicity by intravenous injection of liposome-entrapped catalase and superoxide dismutase. *J Clin Invest* **73**:87-95, 1984.
26. Beckman JS, Minor CW, White CW, Repine JE, Rosen GM, Freeman BA. Superoxide dismutase and catalase conjugated to polyethylene glycol increases endothelial enzyme activity and oxidant resistance. *J Biol Chem* **263**:6884-6892, 1988.
27. White CW, Jackson JH, Abuchowski A, Kazo GM, Mimmack RF, Berger EM, Freeman BA, McCord JM, Repine JE. Polyethylene glycol-attached antioxidant enzymes decrease pulmonary oxygen toxicity in rats. *J Appl Physiol* **66**:584-690, 1989.
28. Padmanabhan RV, Gudapaty R, Liener IE, Schwartz BA, Hoidal JR. Protection against pulmonary oxygen toxicity in rats by the

- tracheal administration of liposome-encapsulated superoxide dismutase or catalase. *Am Rev Respir Dis* **132**:164–167, 1985.
29. Tang G, White JE, Gordon RJ, Lumb PD, Tsan MF. Polyethylene glycol-conjugated superoxide dismutase protects rats against oxygen toxicity. *J Appl Physiol* **74**:1425–1431, 1993.
 30. Jacobson JM, Michael JR, Jafri MA, Gurtner GH. Antioxidant enzymes protect against pulmonary oxygen toxicity in the rabbit. *J Appl Physiol* **68**:1252–1259, 1990.
 31. Frank L, Yam J, Roberts RJ. The role of endotoxin in protection of adult rats from oxygen-induced lung toxicity. *J Clin Invest* **61**:269–275, 1978.
 32. Frank L, Summerville J, Massaro D. Protection from oxygen toxicity with endotoxin: Role of the endogenous antioxidant enzymes of the lung. *J Clin Invest* **65**:1104–1110, 1980.
 33. Hass MA, Iqbal J, Clerch LB, Frank L, Massro D. Rat lung Cu,Zn superoxide dismutase. Isolation and sequence of a full-length cDNA and studies of enzyme induction. *J Clin Invest* **83**:1241–1246, 1989.
 34. Iqbal J, Clerch LB, Hass MA, Frank L, Massro D. Endotoxin increases lung Cu,Zn superoxide dismutase mRNA: O₂ raises enzyme synthesis. *Am J Physiol* **257**:L61–L64, 1989.
 35. Massaro D, Rahman I, Clerch LB, Iqbal J. Tolerance of rats to hyperoxia: Lung antioxidant enzyme gene expression. *FASEB J* **6**:A1816, 1992.
 36. Tsan MF, White JE, Santana TA, Lee CY. Tracheal insufflation of tumor necrosis factor protects rats against oxygen toxicity. *J Appl Physiol* **68**:1211–1219, 1990.
 37. Tsan MF, Lee CY, White JE. Interleukin 1 protects rats against oxygen toxicity. *J Appl Physiol* **71**:688–697, 1991.
 38. Tsan MF, White JE, Treanor C, Shaffer JB. Molecular basis for tumor necrosis factor-induced increase in pulmonary superoxide dismutase activities. *Am J Physiol* **259**:L506–L512, 1990.
 39. Tsan MF, White JE. Kinetics of pulmonary superoxide dismutase in interleukin-1-induced oxygen tolerant rats. *Am J Physiol* **263**:L342–L347, 1992.
 40. Tsan MF, White JE, Del Vecchio PJ, Shaffer JB. IL-6 enhances TNF- and IL-1-induced increase of Mn-superoxide dismutase mRNA and oxygen tolerance. *Am J Physiol* **263**:L22–L26, 1992.
 41. Tsan MF, White JE, Wong GHW. D-factor and growth hormone enhance tumor necrosis factor-induced increase of Mn superoxide dismutase mRNA and oxygen tolerance. *Cytokine* **4**:101–105, 1992.
 42. Jensen JC, Pogrebniak HW, Pass HI, Buresh C, Merino MJ, Kauffman D, Venzon D, Langstein HW, Norton JA. Role of tumor necrosis factor in oxygen toxicity. *J Appl Physiol* **75**:1902–1907, 1992.
 43. Wispe JR, Warner BB, Clark JC, Dey CR, Neuman J, Glasser SW, Crapo JD, Chang LY, Whitsett JA. Human Mn-superoxide dismutase in pulmonary epithelial cells of transgenic mice confers protection from oxygen injury. *J Biol Chem* **267**:23937–23941, 1992.
 44. Visner GA, Block ER, Burr IM, Nick HS. Regulation of manganese superoxide dismutase in porcine pulmonary artery endothelial cells. *Am J Physiol* **260**:L444–L449, 1991.
 45. Valentine JF, Nick HS. Acute-phase induction of manganese superoxide dismutase in intestinal epithelial cell lines. *Gastroenterology* **103**:905–912, 1992.
 46. Visner GA, Chesrown SE, Monnier J, Ryan US, Nick HS. Regulation of manganese superoxide dismutase: IL-1 and TNF induction in pulmonary artery and microvascular endothelial cells. *Biochem Biophys Res Commun* **188**:453–462, 1992.
 47. Hazinski TA, Kennedy KA, France ML, Hansen TN. Pulmonary O₂ toxicity in lambs: Physiological and biochemical effects of endotoxin infusion. *J Appl Physiol* **65**:1579–1585, 1988.
 48. White CW, Ghezzi P, Dinarello CA, Caldwell SA, McMurty IF, Repine JE. Recombinant tumor necrosis factor/cachectin and interleukin 1 pretreatment decreases lung oxidized glutathione accumulation, lung injury, and mortality in rats exposed to hyperoxia. *J Clin Invest* **79**:1868–1873, 1987.
 49. White CW, Ghezzi P, McMahan S, Dinarello CA, Repine JE. Cytokines increase rat lung antioxidant enzyme during exposure to hyperoxia. *J Appl Physiol* **66**:1003–1007, 1989.
 50. Berg JT, Allison RC, Prasad VR, Taylor AE. Endotoxin protection of rats from pulmonary oxygen toxicity: Possible cytokine involvement. *J Appl Physiol* **68**:549–553, 1990.
 51. Witschi HR, Haschek WM, Klein-Szanto AJP, Hakkinen PJ. Potentiation of diffuse lung damage by oxygen: Determining variables. *Am Rev Respir Dis* **123**:98–103, 1981.